CIK 0001842295
- Non-accelerated filer
- Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-850-5070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-08 | Lim Jonathan E Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | Lim Jonathan E Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-02-03 | Lim Jonathan E Director | Conversion | +37,724 | 37,724 | ||
| 2025-02-03 | Lim Jonathan E Director | Conversion | +270,232 | 307,956 | ||
| 2025-02-03 | Lim Jonathan E Director | Conversion · Series A Preferred Stock | −363,703 | 0 | ||
| 2025-02-03 | Lim Jonathan E Director | Conversion · Series B Preferred Stock | −2,231,381 | 0 | ||
| 2024-12-09 | Lim Jonathan E Director | Grant or award · Stock Option (Right to Buy) | +5,704 | 5,704 | ||
| 2024-12-09 | Lim Jonathan E Director | Returned to the company · Stock Option (Right to Buy) | −5,704 | 0 | ||
| 2024-12-09 | Lim Jonathan E Director | Grant or award · Stock Option (Right to Buy) | +9,086 | 9,086 |
Page 1 of 1 · 9 trades